News

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan
Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...
Business Wire3d
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
Sarepta Therapeutics rises after restructuring, pipeline focus
Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...
Business Insider6mon
Sarepta Therapeutics: A Buy Rating Backed by Strong Elevidys ...
In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00.
Yahoo Finance3mon
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the ...
Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Nasdaq7mon
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? - Nasdaq
The surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys – A Key Driver of Sarepta’s Top line ...